IAG works with clients to de-risk clinical development and deliver therapies to patients. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes.
Since 2007, we helped our partners to face the challenges to successful drug development by transferring our scientific expertise, operational practices and technology innovation to their organizations.
For more than 15 years, we worked on many studies, engaged with sites all around the world, for number of therapeutics areas like musculoskeletal, oncology, immunology, rheumatology, CNS and rare disease trials. During this time IAG became a chosen partner for imaging studies of dozen of biotech and pharmaceutical companies, clinical research organization and public institutions.
To manage our projects, we use our benchmarking libraries, DYNAMIKA – our proprietary cloud-based platform – and expert advisory board to diligently design your trial and to choose the right biomarkers and endpoints so that we can accurately project costs and timelines, discover risks and identify potential regulatory issues or barriers to approval.
We understand each trial needs to deliver scientifically credible data, which is often pivotal to any future developments of your assets as well as financial health of the company. Want to learn more about our previous results and the IAG’s added values? Follow the links below and explore our multiple case studies.